Exclusive Risperdal Mass Tort Lead Generation Platform
Connect your law firm with pre-screened, high-intent Risperdal claimants in real time. PingTree Systems' intelligent lead distribution engine delivers verified leads directly to your intake team — so you focus on winning cases, not chasing prospects.
What Is Risperdal & Why Does It Matter Legally?
Risperdal (risperidone) is a second-generation atypical antipsychotic medication manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. Originally approved by the FDA in 1993, the drug was prescribed to treat schizophrenia, bipolar disorder, and behavioral symptoms associated with autism spectrum disorders.
Over time, Risperdal was widely prescribed "off-label" for conditions including anxiety, depression, sleep disorders, and ADHD — uses that fell outside its FDA-approved scope. The drug works by modulating dopamine, serotonin, and norepinephrine receptor activity in the brain. While effective for some patients, this mechanism also triggers elevated prolactin levels, a protein that stimulates breast tissue development.
Invega (Paliperidone)
Invega, the active metabolite of Risperdal known as paliperidone, carries similar risks and has also been at the center of litigation. Both drugs were promoted for conditions beyond their approved indications, and both have generated significant legal exposure for Janssen and Johnson & Johnson.
⚠️ Legal Context: J&J paid approximately $2.2 billion in a 2013 federal settlement related to unlawful promotion of Risperdal and other drugs — one of the largest pharmaceutical criminal settlements in U.S. history. Individual civil claims continue to be filed.
Risperdal Litigation: Key Cases & Settlements
The Risperdal litigation is among the most extensive pharmaceutical mass tort cases in U.S. legal history. Here's what your firm needs to know about the legal landscape.
Notable State-Level Settlements
In addition to federal criminal proceedings, numerous states pursued their own actions against J&J and Janssen for Medicaid fraud and improper marketing.
District of Columbia + 36 States
(2012 multi-state settlement)
Texas
(Medicaid fraud settlement)
South Carolina
(later reduced on appeal)
Allegations Against Janssen / J&J
- Fraudulent and misleading drug labeling
- Unlawful off-label marketing to children, elderly, and veterans
- Illegal kickback payments to physicians and nursing home chains
- Deliberate suppression of known side effect data
- Inadequate warning labels for gynecomastia risk
- Negligent misrepresentation to regulatory bodies
Federal Criminal Plea (2013)
J&J's Janssen Pharmaceuticals subsidiary pleaded guilty to a federal misdemeanor charge for misbranding Risperdal with intent to defraud and mislead. The company agreed to pay $2.2 billion — comprised of criminal fines and civil settlements — one of the largest healthcare fraud resolutions in U.S. Department of Justice history.
The U.S. Attorney's office found that J&J paid illegal remuneration to promote the drug for uses not approved as safe and effective by the FDA, including use in elderly dementia patients and children with behavioral disorders.
Serious Side Effects Driving Litigation
These adverse outcomes form the basis of most Risperdal personal injury claims. Understanding them helps law firms identify qualified claimants quickly and accurately.
Gynecomastia
The most widely reported side effect — abnormal development of male breast tissue caused by elevated prolactin levels. It predominantly affected boys and young men who were prescribed the drug during developmental years, sometimes requiring surgical correction.
Galactorrhea
Inappropriate breast milk production in both males and pre-pubescent females. This condition is directly tied to the drug's effect on prolactin production and has been reported in patients as young as four years old.
Tardive Dyskinesia
A neurological disorder causing repetitive, involuntary facial movements. Often irreversible, this condition develops with long-term antipsychotic use and has led to significant personal injury awards in Risperdal cases.
Cognitive & Developmental Impact
Children prescribed Risperdal off-label for ADHD or behavioral issues experienced documented developmental and psychological side effects, forming the basis of many pediatric-focused claims.
Hormonal Disruption
Sustained elevation of prolactin affects the endocrine system broadly, potentially causing sexual dysfunction, infertility, and bone density loss — all of which have been cited in civil litigation against Janssen.
Stroke & Cardiovascular Risk
Elderly patients prescribed Risperdal for dementia-related behavioral symptoms faced elevated stroke and mortality risk. The FDA issued a black box warning regarding this population, adding further legal weight to claims.
How PingTree Risperdal Lead Delivery Works
From claimant intake to real-time delivery — our four-step process ensures your firm receives only qualified, high-intent Risperdal leads ready for intake interviews.
Claimant Identification
Our multi-channel campaigns capture individuals who used Risperdal or Invega and experienced documented adverse side effects including gynecomastia or galactorrhea.
Qualification & Screening
Each lead is screened against your firm's specific criteria — drug name, usage period, diagnosed side effect, age at usage, and documentation availability — before entering the distribution queue.
Ping-Tree Distribution
Using our proprietary ping-post technology, qualified leads are matched to registered buyer firms based on geography, budget caps, and case criteria — in real time, within seconds of submission.
Intake & Conversion
Your intake team receives the lead instantly with full contact details, consent records, and screening notes — enabling immediate follow-up while claimant intent is at its peak.
Why Law Firms Choose PingTree for Mass Tort Leads
Our lead distribution platform is purpose-built for the demands of high-volume mass tort campaigns, combining automation, compliance, and real-time intelligence.
Real-Time Lead Delivery
Leads are transmitted to your CRM or intake system within 60 seconds of qualification, ensuring you reach claimants while their interest is highest.
Custom Qualification Filters
Define your own intake criteria — drug name, injury type, state, usage timeframe — and receive only the leads that match your case profile precisely.
TCPA-Compliant Leads
All leads are gathered with proper consumer consent under TCPA guidelines, protecting your firm from compliance exposure during outreach campaigns.
Live Dashboard & Analytics
Monitor lead volume, conversion rates, cost-per-acquisition, and ROI in real time through a clean, intuitive dashboard built for legal marketing teams.
CRM & Case Management Integration
Seamless integration with Salesforce, Clio, Filevine, LeadDocket, and other legal CRM platforms ensures no lead falls through the cracks at intake.
Flexible Pricing Models
Choose from cost-per-lead, exclusive leads, or shared lead pricing. Set daily and monthly budget caps so your campaign scales with your intake capacity.
Explore More Mass Tort & Legal Lead Solutions
PingTree Systems powers lead generation across the full spectrum of mass tort and legal practice areas. Discover related solutions for your firm.
Also explore: Lead Distribution Software Platform Features Pricing Integrations
Frequently Asked Questions About Risperdal Leads
Ready to Build Your Risperdal Case Pipeline?
Join hundreds of law firms using PingTree Systems to receive verified, pre-screened Risperdal claimant leads in real time.